{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:50:16Z","timestamp":1760057416601,"version":"build-2065373602"},"reference-count":19,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: The aim of our study is to compare the effects of pirfenidone and nintedanib on lung function and radiologic findings in Idiopathic Pulmonary Fibrosis and to identify which drug is more appropriate for which patient group. Materials and Methods: The data of patients who were treated in our department for at least one year between 1 January 2010 and 31 December 2022 and who were started on pirfenidone or nintedanib treatment with the diagnosis of Idiopathic Pulmonary Fibrosis were retrospectively reviewed. The patients were divided into two groups\u2014the nintedanib and pirfenidone groups\u2014and both groups were compared in terms of progression in lung function tests (changes in FEV1, FVC, 6 MWT and DLCO values at the 3rd, 6th, 9th and 12th months compared to baseline values) and radiological findings (the presence of progression in findings such as ground-glass opacity, reticulation, honeycomb and traction bronchiectasis) within 1 year after diagnosis. Results: The study included 109 patients. The number of patients treated with pirfenidone (IPF patients) was 82 (75.2%) and the number of patients treated with nintedanib was 27 (24.8%). When the PFT values at 3, 6, 9 and 12 months were compared with the baseline values in both groups, there was no statistically significant difference in any parameter between the two groups. No significant difference was found in terms of radiological progression at the end of 1 year in both groups. Conclusions: The results of our study show that pirfenidone and nintedanib are equivalent in their effectiveness in preventing disease progression in patients with IPF.<\/jats:p>","DOI":"10.3390\/medicina61020283","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T11:32:32Z","timestamp":1738841552000},"page":"283","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of the Effects of Nintedanib and Pirfenidone on Pulmonary Function Test Parameters and Radiological Findings in Patients with Idiopathic Pulmonary Fibrosis: A Real-Life Study"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0697-5680","authenticated-orcid":false,"given":"Olcay","family":"Aycicek","sequence":"first","affiliation":[{"name":"Department of Chest Disease, Faculty of Medicine, Karadeniz Technical University, Trabzon 61100, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serra","family":"Keskin","sequence":"additional","affiliation":[{"name":"Department of Chest Disease, Faculty of Medicine, Karadeniz Technical University, Trabzon 61100, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammed","family":"Haciosmanoglu","sequence":"additional","affiliation":[{"name":"Department of Chest Disease, Faculty of Medicine, Karadeniz Technical University, Trabzon 61100, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Funda","family":"Oztuna","sequence":"additional","affiliation":[{"name":"Department of Chest Disease, Faculty of Medicine, Karadeniz Technical University, Trabzon 61100, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yilmaz","family":"Bulbul","sequence":"additional","affiliation":[{"name":"Department of Chest Disease, Faculty of Medicine, Karadeniz Technical University, Trabzon 61100, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tevfik","family":"Ozlu","sequence":"additional","affiliation":[{"name":"Department of Chest Disease, Faculty of Medicine, Karadeniz Technical University, Trabzon 61100, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0140-6736(17)30866-8","article-title":"Idiopathic pulmonary fibrosis","volume":"389","author":"Richeldi","year":"2017","journal-title":"Lancet"},{"key":"ref_2","unstructured":"Aycicek, O., Cetinkaya, E., Ucsular, F.D., Bayram, N., Senyigit, A., Aksel, N., Atilla, N., Sar\u0131oglu, N., Niksarl\u0131oglu, E.Y., and Ilgazl\u0131, A. (2022). Research Burden of Interstitial Lung Diseases in Turkey\u2014RBILD. Sarcoidosis Vasc. Diffus. Lung Dis., 39."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1164\/rccm.200602-163OC","article-title":"Incidence and Prevalence of IdiopathicPulmonary Fibrosis","volume":"174","author":"Raghu","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ses\u00e9, L., Nunes, H., Cottin, V., Israel-Biet, D., Crestani, B., Guillot-Dudoret, S., Cadranel, J., Wallaert, B., Tazi, A., and Ma\u00eetre, B. (2021). Gender Differences in Idiopathic Pulmonary Fibrosis: Are Men and Women Equal?. Front. Med., 8.","DOI":"10.3389\/fmed.2021.713698"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Amati, F., Stainer, A., Polelli, V., Mantero, M., Gramegna, A., Blasi, F., and Aliberti, S. (2023). Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24097849"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.chest.2021.06.049","article-title":"Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis A Systematic Review and Meta-Analysis","volume":"160","author":"Petnak","year":"2021","journal-title":"Chest"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"205","author":"Raghu","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: A double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): A double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Margaritopoulos, G.A., Trachalaki, A., Wells, A.U., Vasarmidi, E., Bibaki, E., Papastratigakis, G., Detorakis, S., Tzanakis, N., and Antoniou, K.M. (2018). Pirfenidone improves survival in IPF: Results from a real-life study. Pulm. Med., 18.","DOI":"10.1186\/s12890-018-0736-z"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.rmed.2019.04.016","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment","volume":"153","author":"Nathan","year":"2019","journal-title":"Respir. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for Systemic Sclerosis\u2013Associated Interstitial Lung Disease","volume":"380","author":"Distler","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in Progressive Fibrosing Interstitial Lung Diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.pulmoe.2018.06.003","article-title":"Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis:Real-life experience in an Italian referral centre","volume":"25","author":"Bargagli","year":"2019","journal-title":"Pulmonolgy"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Cerri, S., Monari, M., Guerrieri, A., Donatelli, P., Bassi, I., Garuti, M., Luppi, F., Betti, S., Bandelli, G., and Carpano, M. (2019). Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment. Respir. Med., 159.","DOI":"10.1016\/j.rmed.2019.105803"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Cameli, P., Refini, R.M., Bergantini, L., d\u2019Alessandro, M., Alonzi, V., Magnoni, C., Rottoli, P., Sestini, P., and Bargagli, E. (2020). Long-Term Follow-Up of Patients with Idiopathic Pulmonary Fibrosis Treated with Pirfenidone or Nintedanib: A Real-Life Comparison Study. Front. Mol. Biosci., 4.","DOI":"10.3389\/fmolb.2020.581828"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Marijic, P., Schwarzkopf, L., Schwettmann, L., Ruhnke, T., Trudzinski, F., and Kreuter, M. (2021). Pirfenidone vs. nintedanib inpatients withidiopathic pulmonary fbrosis: Aretrospective cohort study. Respir. Res., 22.","DOI":"10.1186\/s12931-021-01857-y"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.chest.2023.11.035","article-title":"Comparison of Pirfenidone and Nintedanib. Post Hoc Analysis of the CleanUP-IPF Study","volume":"165","author":"Kim","year":"2024","journal-title":"Chest"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/2\/283\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:28:19Z","timestamp":1760027299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/2\/283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["medicina61020283"],"URL":"https:\/\/doi.org\/10.3390\/medicina61020283","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2025,2,6]]}}}